Search results for: receptor
#35752964 
2022/06/20
To Up
Introducing innovative cellular therapies into the clinic: a 2-year retrospective experience of a chimeric antigen receptor T-cell programme at a single centre in Switzerland.
Chimeric antigen receptor T (CAR-T) cells are a powerful form of immune-cell therapy for patients with relapsed/refractory B-cell lymphoma and acute B lymphoblastic leukaemia. CAR-T cells have been commercially available in Switzerland since 2018. Because of the complexity and costs of this treatment it is critical to review patient outcomes in real-world settings, to examine whether the promising results from pivotal trials can be reproduced and to identify clinical parameters that determine their efficacy.Sebastian Stolz, Marco Roncador, Wiebke Rösler, Thorsten Zenz, Markus G Manz, Antonia M S Müller, Corinne C Widmer
2494 related Products with: Introducing innovative cellular therapies into the clinic: a 2-year retrospective experience of a chimeric antigen receptor T-cell programme at a single centre in Switzerland.
100 ug/vial0.1ml (1mg/ml)96T0.1ml (1mg/ml)2 Pieces/Box96 assays100ug1mg0.1ml1 mg96 tests
Related Pathways
#35752862 2022/06/25
To Up
An N-glycoproteomic site-mapping analysis reveals glycoprotein alterations in esophageal squamous cell carcinoma.
Aberrant glycosylation has been recognized as a hallmark of cancer and N-glycosylation is one of the main types of glycosylation in eukaryotes. Although N-glycoproteomics has made contributions to the discovery of biomarkers in a variety of cancers, less is known about the abnormal glycosylation signatures in esophageal squamous cell carcinoma (ESCC).Yingzhen Gao, Liuyi Shen, Tianyue Dong, Xin Yang, Heyang Cui, Yanlin Guo, Yanchun Ma, Pengzhou Kong, Xiaolong Cheng, Ling Zhang, Yongping Cui
2677 related Products with: An N-glycoproteomic site-mapping analysis reveals glycoprotein alterations in esophageal squamous cell carcinoma.
96tests96tests
Related Pathways
#35752765 2022/06/25
To Up
The evolution of vitamin C biosynthesis and transport in animals.
Vitamin C (VC) is an indispensable antioxidant and co-factor for optimal function and development of eukaryotic cells. In animals, VC can be synthesized by the organism, acquired through the diet, or both. In the single VC synthesis pathway described in animals, the penultimate step is catalysed by Regucalcin, and the last step by L-gulonolactone oxidase (GULO). The GULO gene has been implicated in VC synthesis only, while Regucalcin has been shown to have multiple functions in mammals.Pedro Duque, Cristina P Vieira, Bárbara Bastos, Jorge Vieira
2859 related Products with: The evolution of vitamin C biosynthesis and transport in animals.
900 tests1100ug Lyophilized100ug2ug
Related Pathways
#35752730 2022/06/25
To Up
Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries.
Insulin degludec/insulin aspart (IDegAsp) is a fixed-ratio co-formulation of insulin degludec (a basal insulin) and insulin aspart (a prandial insulin). The aim of this study was to investigate clinical outcomes in people with type 2 diabetes (T2D) after initiating IDegAsp treatment in a real-world setting.Gregory R Fulcher, Shahid Akhtar, Saleh J Al-Jaser, Johan Medina, Mafauzy Mohamed, Nemencio A Nicodemus, Anne Helene Olsen, Kiran P Singh, Adri Kok
1388 related Products with: Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries.
100ug100.00 ug100ug100ug100ug100ug Lyophilized100ug100ug Lyophilized100ug Lyophilized1 kit100ug
Related Pathways
#35752711 2022/06/25
To Up
Ribonuclease 4 is associated with aggressiveness and progression of prostate cancer.
Prostate specific antigen screening has resulted in a decrease in prostate cancer-related deaths. However, it also has led to over-treatment affecting the quality of life of many patients. New biomarkers are needed to distinguish prostate cancer from benign prostate hyperplasia (BPH) and to predict aggressiveness of the disease. Here, we report that ribonuclease 4 (RNASE4) serves as such a biomarker as well as a therapeutic target. RNASE4 protein level in the plasma is elevated in prostate cancer patients and is positively correlated with disease stage, grade, and Gleason score. Plasma RNASE4 level can be used to predict biopsy outcome and to enhance diagnosis accuracy. RNASE4 protein in prostate cancer tissues is enhanced and can differentiate prostate cancer and BPH. RNASE4 stimulates prostate cancer cell proliferation, induces tumor angiogenesis, and activates receptor tyrosine kinase AXL as well as AKT and S6K. An RNASE4-specific monoclonal antibody inhibits the growth of xenograft human prostate cancer cell tumors in athymic mice.Nil Vanli, Jinghao Sheng, Shuping Li, Zhengping Xu, Guo-Fu Hu
2499 related Products with: Ribonuclease 4 is associated with aggressiveness and progression of prostate cancer.
1 G100ug Lyophilized100ug Lyophilized100ug LyophilizedEach100ug Lyophilized
Related Pathways
#35752703 2022/06/25
To Up
The prevalence and predictors of adjuvant chemotherapy use among patients treated with neoadjuvant endocrine therapy.
Neoadjuvant endocrine therapy (NET) facilitates clinical response and breast conservation in hormone receptor-positive (HR-positive) breast cancer. Patient selection for adjuvant chemotherapy (CT) post-NET is unclear and potentially evolving with use of genomic assays. We evaluated post-NET CT use in a national dataset.Tal Sella, Olga Kantor, Anna Weiss, Ann H Partridge, Otto Metzger, Tari A King
2438 related Products with: The prevalence and predictors of adjuvant chemotherapy use among patients treated with neoadjuvant endocrine therapy.
100ug5ug10 mg50 ug 100 mg 100ul10 mg1,000 tests200ug
Related Pathways
#35752699 2022/06/25
To Up
Adenosine A receptor as a potential target for improving cancer immunotherapy.
The adenosine nucleoside performs a wide range of actions on various human tissues by activating four cell surface receptors. Adenosine A receptors (ARs) are widely expressed in the striatum, olfactory bulb, platelets, leukocytes, spleen, and thymus. They promote vasodilatation, platelet antiaggregatory effect, protection from ischemic damage, and regulation of sensorimotor neurons in basal ganglia. Adenosine signaling plays a vital part in modulating in vivo pathophysiological responses. ARs are potent negative regulators of the antitumor and proinflammatory actions of activated T cells. This axis offers several therapeutic targets, the most important of which are ARs, HIF-1α, and CD39/CD73. Downregulation of this axis increases the effectiveness of modern immunotherapeutic approaches against cancer, such as αCTLA-4/αPD-1. These discoveries have led to a promising novel role of antagonists of AR in blocking angiogenesis in immunotherapy of cancer. A small molecule, AZD4635, strongly inhibits AR, lowering cancer volume and increasing anticancer immunity. Deletion of AR with CRISPR/Cas9 in both human and murine CAR T cells produces a substantial increase in the efficiency of these cells. This review asserts that inhibition of the adenosinergic pathway can boost antitumor immunity, and this axis should be a target for future immunotherapeutic strategies.Muhammad Atif, Abdullah Alsrhani, Farrah Naz, Muhammad Ikram Ullah, Ayman Ali Mohammed Alameen, Muhammad Imran, Hasan Ejaz
1988 related Products with: Adenosine A receptor as a potential target for improving cancer immunotherapy.
50ul100 μg96T100 ml100ul1 kit50μl100 plates200ul200ul100 assays0.2 mg
Related Pathways